51535-01-4 Usage
General Description
1-Benzyl-3-(chloromethyl)pyrrolidine is a chemical compound that belongs to the group of pyrrolidines and piperidines, commonly used in chemical and pharmaceutical research. This chemical is characterized by the presence of a pyrrolidine ring, a five-membered ring with one nitrogen atom, a benzyl group, which is a phenyl ring with a methyl substituent, and a chloromethyl group attached to the nitrogen atom of the pyrrolidine ring. These groupings provide it with unique properties, typically making it a useful building block in organic synthesis. Its hazard details and safety measures are detailed in its corresponding material safety data sheet. It is advised to handle this compound in a controlled environment due to its potential harmful effects.
Check Digit Verification of cas no
The CAS Registry Mumber 51535-01-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,5,3 and 5 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 51535-01:
(7*5)+(6*1)+(5*5)+(4*3)+(3*5)+(2*0)+(1*1)=94
94 % 10 = 4
So 51535-01-4 is a valid CAS Registry Number.
51535-01-4Relevant articles and documents
LTA4 Hydrolase inhibitors
-
Page 43, 198, (2010/01/31)
The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.
